April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Structural and Functional Neuroprotection in Glaucoma: Role of Galantamine-Mediated Activation of Muscarinic Acetylcholine Receptors
Author Affiliations & Notes
  • M. Almasieh
    Pathology/Cell Biology,
    Universite de Montreal, Montreal, Quebec, Canada
  • Y. Zhou
    Department of Pediatric Surgery, Nationwide Children's Hospital, Columbus, Ohio
  • M. E. Kelly
    Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
  • C. Casanova
    School of Optometry,
    Universite de Montreal, Montreal, Quebec, Canada
  • A. Di Polo
    Pathology/Cell Biology,
    Universite de Montreal, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  M. Almasieh, None; Y. Zhou, None; M.E. Kelly, None; C. Casanova, None; A. Di Polo, None.
  • Footnotes
    Support  CIHR Grant PPP-79112, American Health Assistance Foundation/National Glaucoma Research Grant G2008-027
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3178. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Almasieh, Y. Zhou, M. E. Kelly, C. Casanova, A. Di Polo; Structural and Functional Neuroprotection in Glaucoma: Role of Galantamine-Mediated Activation of Muscarinic Acetylcholine Receptors. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3178.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Galantamine is an acetylcholinesterase inhibitor and allosteric ligand of nicotinic ACh receptors (AChR) that is used clinically for the treatment of Alzheimer’s disease. We examined whether galantamine provides structural and functional neuroprotection of retinal ganglion cells (RGCs) after optic nerve damage, and addressed the molecular mechanisms underlying galantamine-mediated neuroprotection.

Methods: : Optic nerve damage was induced by ocular hypertension (OHT), after injection of hypertonic saline into an episcleral vein (Morrison model), or by axotomy. Galantamine was administered daily by intraperitoneal injection. RGC neuroprotection was assessed by: i) quantification of retrogradely labeled RGCs, ii) axon counts obtained from optic nerve semi-thin sections, and iii) visual evoked potentials (VEP) measured from the superior colliculus. The role of AChR was established using selective antagonists for nicotinic AChR or muscarinic AChR.

Results: : Our data demonstrate that galantamine promotes structural and functional RGC protection following chronic (experimental glaucoma) or acute (axotomy) optic nerve injury. Quantitative analysis confirmed that galantamine led to a striking increase in RGC survival (~90%, n=11) at 3 weeks after OHT surgery compared to vehicle (55%, n=9). Although neuronal damage was more severe at 5 weeks after OHT surgery, galantamine protected ~70% of RGC soma (n=10) compared to only 37% with PBS (n=9) (ANOVA, p < 0.001). Importantly, functional deficits caused by high IOP were markedly improved by galantamine. Quantification of peak-to-peak VEP amplitudes showed that galantamine preserved 66% of the intact VEP response compared to only 30% in controls. Pharmacological block of either nAChR or mAChR indicated that galantamine-mediated neuroprotection occurred through activation of retinal muscarinic AChR types M1 and M4, while nicotinic AChR were not involved.

Conclusions: : Our study supports the therapeutic potential of galantamine in glaucoma and reveals mAChR as a potential clinical target for this neurodegenerative disease.

Keywords: neuroprotection • optic nerve • acetylcholine 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×